"Designing Growth Strategies is in our DNA"
Region : Global | Published Date: Upcoming | Report ID: FBI100607| Status : Upcoming
Leukemia is a type of cancer that mainly occurs in white blood cells. White blood cells function for the immune system and are produced in the bone marrow. In the case of leukemia, the bone marrow produces abnormal white blood cells. There are different types of leukemia based on their growth of the cells, namely acute (slow-growing) and chronic (fast-growing). Based on their growth in cells, they are classified as myeloid cells or lymphoid cells. Acute myeloid leukemia occurs in the bone marrow and rapidly spreads, affecting different parts of the body such as the liver, spleen, central nervous system, lymph nodes, and testicles.
To get information on various segments, share your queries with us
According to the American Cancer Society, in 2019, the number of new acute myeloid leukemia cases is estimated to be 21,450 in the U.S. The rising prevalence of acute myeloid leukemia and unmet needs of the patients have resulted in an increased focus on the development of new drugs. New drug approvals for the acute myeloid leukemia treatment, namely Rydapt by Novartis AG, is expected to drive the growth of global acute myeloid leukemia treatment market.
The rise in incidences of genetic mutations, sedentary lifestyles, high exposure to radiations are some factors leading to an increased incidence in acute myeloid leukemia globally. Moreover, the presence of potential pipeline candidates, new product launch, and increased investment by the pharmaceutical industry and research institutes are also expected to boost the market in the forecast duration.
However, high cost associated with stem cell transplantation and risk of side effects from the drugs are the major factors restricting the growth in the global acute myeloid leukemia treatment market
Some of the major companies that are present in the global acute myeloid leukemia treatment market are VERASTEM, INC., Genzyme Corporation, Neomed Management AS, Sunesis Pharmaceuticals Inc., Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc., and others.
By Disease Type
By Treatment Type
· Targeted Therapy
By Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Pharmacy
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Based on the treatment type, the chemotherapy segment is expected to dominate the global acute myeloid leukemia treatment market owing to the increased availability of the drugs, increased preference and increased R&D investment for the development of innovative drugs.
Prevalence of acute myeloid leukemia
The regulatory scenario for key countries
Reimbursement Scenario for key countries
New product launch
Recent industry developments such as partnerships, mergers, and acquisitions
North America is anticipated to hold a considerable share in the global acute myeloid leukemia treatment market during the forecast period due to the increasing demand, favorable health reimbursement, and strategic research collaborations. The acute myeloid leukemia treatment market in Europe is expected to expand owing to the active government support, increasing prevalence of the disease, and emphasis on early cancer diagnosis by government. Asia Pacific is estimated to register a remarkable growth in the projected duration owing to the developing health infrastructure and increased government expenditure for the treatment of cancer. Also, inclination towards targeted therapies than the traditional methods is anticipated to fuel the growth in global acute myeloid leukemia treatment market in Asia Pacific during the forecast period.
· In December 2018, Astellas Pharma Inc., launched XOSPATA (gilteritinib) for treating adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation in the U.S.
· In November 2018, Pfizer Inc. received FDA approval for Cglasdegib (Daurismo) for patients who are newly-diagnosed with acute myeloid leukemia (AML).
· In November 2018, Genentech, Inc. received FDA approval for the Venclexta for the treatment of patients who are newly-diagnosed with acute myeloid leukemia or patients who are not eligible for intensive induction chemotherapy.
· In April 2017, Novartis AG received FDA approval for Rydapt for patient with newly diagnosed acute myeloid leukemia (AML) with FLT3-mutation and certain types of systemic mastocytosis (SM)